Business
P140 Program Update
ImmuPharma PLC has announced positive progress on its P140 auto-immune technology platform, receiving a supportive first Combined Search and Examination Report for its UK patent application filed in September 2025, with plans for a PCT application to seek protection in key commercial territories. The company also completed a new study with positive results supporting the patent application, and a scientific manuscript detailing the P140 technology and its mechanism of action is in preparation for submission to a peer-reviewed journal. ImmuPharma continues to progress discussions with potential partners for P140, aiming to complete a value-enhancing licensing deal in 2026. Disclaimer*
About this update from Immupharma Plc
[{"type":"text","content":"\n\nThis announcement contains inside information for the purposes of the UK Market Abuse Regulations ('UK MAR'). Upon publication of this announcement, this inside information (as defined in UK MAR) is now considered to be in the public domain. The person responsible for arranging the release of this announcement on behalf of the Company is tim mccarthy, Chief Executive Officer.\n \n \n27 March 2026\n \n\n \nImmuPharma PLC\n(\"ImmuPharma\" or the \"Company\")\n \nP140 Program Update\n- patent progress |new supporting data | scientific publication in preparation -\nImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to provide an update on its auto-immune technology platform program, P140.\nThe Company has received a first Combined Search and Examination Report (\"CSER\") in relation to its United Kingdom patent application for P140, filed in September 2025. The supportive response is as expected by management at this stage of the patent examination process and represents an important positive milestone in the ongoing progress of the application. ImmuPharma intends, in due course, to build on this filing through a Patent Cooperation Treaty (\"PCT\") application, with a view to seeking protection in key commercial territories. (See notes).\nIn parallel, ImmuPharma has completed a new study, intended to provide further supporting data for the patent application. The study was designed to stress test the associated diagnostic test and strengthen the statistical significance of the supporting dataset. The Company is pleased to report that the results were positive and supportive of the patent application.\nThe scientific team, led by Dr Sébastien Goudreau, CSO, and Dr Laura Mauran, Head of R&D, is preparing a scientific manuscript describing the P140 technology platform and its mechanism of action, including recent supporting data. The Company intends to submit the manuscript to a peer-reviewed journal in due course. Following publication, the findings will be shared more broadly with the scientific community.\nP140 partnering discussions\nAs reiterated in recent announcements, P140 remains a core value driver for ImmuPharma. The Company continues to progress discussions with a number of potential partners, including under signed confidentiality agre...